The KDIGO 2025 guideline for Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) updates diagnosis and treatment recommendations to improve kidney outcomes. It supports more frequent kidney biopsies for early detection and emphasizes managing immune complex injury and kidney damage using therapies like ACE inhibitors, targeted-release budesonide (Nefecon), sparsentan, and SGLT2 inhibitors. The guideline also addresses special populations, including children and pregnant women, and highlights the need for equitable access to these therapies worldwide. These advances reinforce the importance of early diagnosis and tailored treatment to prevent progression to chronic kidney disease or kidney failure.
Source: PubMed
URL: https://pubmed.ncbi.nlm.nih.gov/40975525/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1L1cWENBSM3Im1QGJjxyv8jO1IxZCGB4KTpFMlikldpW6NKAo_&fc=20250922080404&ff=20250922080519&v=2.18.0.post9+e462414[1]
Date: September 22, 2025
References
- Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasc.... https://pubmed.ncbi.nlm.nih.gov/40975525/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1L1cWENBSM3Im1QGJjxyv8jO1IxZCGB4KTpFMlikldpW6NKAo_&fc=20250922080404&ff=20250922080519&v=2.18.0.post9+e462414 Accessed November 7, 2025
